S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Forecast, Price & News

$24.19
+0.47 (+1.98%)
(As of 04:00 PM ET)
Compare
Today's Range
$23.12
▼
$24.22
50-Day Range
$23.72
▼
$31.38
52-Week Range
$21.04
▼
$34.16
Volume
657,952 shs
Average Volume
646,464 shs
Market Capitalization
$1.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

SpringWorks Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
113.3% Upside
$50.50 Price Target
Short Interest
Bearish
23.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of SpringWorks Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$70,872 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.19) to ($4.39) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

746th out of 963 stocks

Biological Products, Except Diagnostic Industry

119th out of 160 stocks

See Top Rated MarketRank™ Stocks Here

SWTX stock logo

About SpringWorks Therapeutics (NASDAQ:SWTX) Stock

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Price History

SWTX Stock News Headlines

September 22, 2023 | finance.yahoo.com
Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Are In A Position To Invest In Growth
September 11, 2023 | markets.businessinsider.com
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
September 25, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
September 11, 2023 | msn.com
SpringWorks Therapeutics gets new chief scientific officer
August 24, 2023 | markets.businessinsider.com
SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update
August 24, 2023 | msn.com
HC Wainwright & Co. Reiterates SpringWorks Therapeutics (SWTX) Buy Recommendation
August 21, 2023 | seekingalpha.com
SpringWorks down 6% on alleged violation of trial protocols
August 8, 2023 | msn.com
HC Wainwright & Co. Maintains SpringWorks Therapeutics (SWTX) Buy Recommendation
September 25, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 2, 2023 | finanznachrichten.de
SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 2, 2023 | finance.yahoo.com
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
July 20, 2023 | msn.com
Goldman Sachs Maintains SpringWorks Therapeutics (SWTX) Buy Recommendation
July 19, 2023 | markets.businessinsider.com
Goldman Sachs Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)
July 12, 2023 | seekingalpha.com
SpringWorks Therapeutics: FDA Decision Date Ahead
July 1, 2023 | fool.com
SpringWorks Therapeutics (NASDAQ: SWTX)
June 28, 2023 | finance.yahoo.com
Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 ‘Strong Buy’ Names With Solid Upside Potential
June 7, 2023 | finance.yahoo.com
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 7, 2023 | msn.com
HC Wainwright & Co. Reiterates SpringWorks Therapeutics (SWTX) Prior Recommendation
June 6, 2023 | msn.com
The Latest Analyst Ratings for SpringWorks Therapeutics
June 5, 2023 | markets.businessinsider.com
Barclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)
June 5, 2023 | msn.com
FDA extends action deadline for SpringWorks nirogacestat drug application
June 5, 2023 | reuters.com
US FDA delays decision on SpringWorks Therapeutics' tumor treatment
June 5, 2023 | markets.businessinsider.com
SpringWorks: FDA Extends PDUFA Date For Nirogacestat NDA
June 5, 2023 | marketwatch.com
SpringWorks Therapeutics: FDA Extends Review of Nirogacestat >SWTX
June 5, 2023 | finance.yahoo.com
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
May 30, 2023 | finance.yahoo.com
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
May 25, 2023 | finance.yahoo.com
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
See More Headlines
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SWTX Company Calendar

Last Earnings
8/02/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SWTX
CUSIP
N/A
CIK
1773427
Web
www.springworkstx.com
Phone
203-883-9490
Fax
N/A
Employees
227
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$50.50
High Stock Price Forecast
$66.00
Low Stock Price Forecast
$41.00
Forecasted Upside/Downside
+111.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.99)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-277,420,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-55.98%
Return on Assets
-49.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.55
Quick Ratio
11.55

Sales & Book Value

Annual Sales
$35 million
Price / Sales
42.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.95 per share
Price / Book
2.67

Miscellaneous

Outstanding Shares
62,570,000
Free Float
57,921,000
Market Cap
$1.49 billion
Optionable
Not Optionable
Beta
0.58

Social Links

10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Saqib Islam J.D.Mr. Saqib Islam J.D. (Age 53)
    CEO & Director
    Comp: $1.26M
  • Mr. Francis I. Perier Jr. (Age 63)
    M.B.A., Chief Financial Officer
    Comp: $710.6k
  • Dr. Badreddin Edris Ph.D. (Age 36)
    Chief Operating Officer
    Comp: $998.61k
  • Dr. L. Mary Smith PH.D. (Age 56)
    Chief Devel. Officer
    Comp: $817.17k
  • Mr. Bhavesh Ashar (Age 57)
    Chief Commercial Officer
    Comp: $729.62k
  • Mr. Michael P. Nofi (Age 52)
    Chief Accounting Officer
  • Mr. Tai-An Lin Ph.D.
    Chief Scientific Officer
  • Ms. Kim Diamond
    VP of Communications & Investor Relations
  • Mr. Herschel S. Weinstein J.D. (Age 67)
    Gen. Counsel & Sec.
  • Mr. Daniel J. Pichl (Age 40)
    Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SWTX Stock - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings or view top-rated stocks.

What is SpringWorks Therapeutics' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price objectives for SpringWorks Therapeutics' shares. Their SWTX share price forecasts range from $41.00 to $66.00. On average, they predict the company's stock price to reach $50.50 in the next twelve months. This suggests a possible upside of 111.6% from the stock's current price.
View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts.

How have SWTX shares performed in 2023?

SpringWorks Therapeutics' stock was trading at $26.01 at the start of the year. Since then, SWTX shares have decreased by 8.2% and is now trading at $23.87.
View the best growth stocks for 2023 here.

When is SpringWorks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our SWTX earnings forecast.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($1.25) earnings per share for the quarter, topping analysts' consensus estimates of ($1.26) by $0.01. During the same quarter in the previous year, the business earned ($1.41) EPS.

What ETFs hold SpringWorks Therapeutics' stock?

ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI).

When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an IPO on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is SpringWorks Therapeutics' stock symbol?

SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.81%), Deep Track Capital LP (5.67%), State Street Corp (5.04%), ArrowMark Colorado Holdings LLC (3.99%), Artal Group S.A. (2.90%) and Perceptive Advisors LLC (2.46%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto.
View institutional ownership trends.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SpringWorks Therapeutics' stock price today?

One share of SWTX stock can currently be purchased for approximately $23.87.

How much money does SpringWorks Therapeutics make?

SpringWorks Therapeutics (NASDAQ:SWTX) has a market capitalization of $1.49 billion and generates $35 million in revenue each year. The company earns $-277,420,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis.

How many employees does SpringWorks Therapeutics have?

The company employs 227 workers across the globe.

Does SpringWorks Therapeutics have any subsidiaries?
The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..
Read More
How can I contact SpringWorks Therapeutics?

SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The official website for the company is www.springworkstx.com. The company can be reached via phone at 203-883-9490 or via email at investors@springworkstx.com.

This page (NASDAQ:SWTX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -